loading
前日終値:
$2.61
開ける:
$2.65
24時間の取引高:
91,117
Relative Volume:
0.13
時価総額:
$167.81M
収益:
-
当期純損益:
$-36.95M
株価収益率:
-3.0893
EPS:
-0.84
ネットキャッシュフロー:
$-33.46M
1週間 パフォーマンス:
-14.19%
1か月 パフォーマンス:
-22.16%
6か月 パフォーマンス:
-63.89%
1年 パフォーマンス:
-70.10%
1日の値動き範囲:
Value
$2.59
$2.70
1週間の範囲:
Value
$2.5417
$3.05
52週間の値動き範囲:
Value
$2.5417
$11.20

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name
名前
Larimar Therapeutics Inc
Name
セクター
Healthcare (1171)
Name
電話
844-511-9056
Name
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Name
職員
42
Name
Twitter
Name
次回の収益日
2025-03-14
Name
最新のSEC提出書
Name
LRMR's Discussions on Twitter

LRMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
LRMR
Larimar Therapeutics Inc
2.595 167.81M 0 -36.95M -33.46M -0.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
510.27 130.68B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
671.38 74.97B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
602.20 36.08B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
243.01 31.19B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.84 27.56B 3.32B -860.46M -1.04B -8.32

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-29 開始されました Truist Buy
2024-10-16 開始されました Oppenheimer Outperform
2024-10-03 開始されました Wedbush Outperform
2024-10-02 開始されました H.C. Wainwright Buy
2024-09-04 開始されました Robert W. Baird Outperform
2024-04-03 開始されました Leerink Partners Outperform
2023-11-17 アップグレード Citigroup Neutral → Buy
2022-10-19 開始されました Guggenheim Buy
2022-02-15 ダウングレード William Blair Outperform → Mkt Perform
2021-02-10 開始されました JMP Securities Mkt Outperform
2021-02-01 開始されました William Blair Outperform
すべてを表示

Larimar Therapeutics Inc (LRMR) 最新ニュース

pulisher
07:22 AM

Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView

07:22 AM
pulisher
Mar 08, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN

Mar 08, 2025
pulisher
Mar 03, 2025

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan

Mar 03, 2025
pulisher
Feb 26, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex

Feb 25, 2025
pulisher
Feb 14, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World

Feb 14, 2025
pulisher
Feb 12, 2025

Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St

Feb 12, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com

Feb 05, 2025
pulisher
Feb 05, 2025

Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Larimar Therapeutics Inc (LRMR)’s stock chart: A technical perspective - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Analysts Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.13 - MarketBeat

Feb 04, 2025
pulisher
Feb 02, 2025

Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Truist Financial - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by JPMorgan Chase & Co. - Defense World

Feb 02, 2025
pulisher
Feb 01, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Buy” from Analysts - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

Truist Financial Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR) - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Larimar started at buy by Truist on Friedreich's ataxia drug - MSN

Jan 30, 2025
pulisher
Jan 29, 2025

Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com

Jan 29, 2025
pulisher
Jan 29, 2025

This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jan 29, 2025
pulisher
Jan 28, 2025

Larimar Therapeutics awards key executives performance-based stock By Investing.com - Investing.com Australia

Jan 28, 2025
pulisher
Jan 28, 2025

Larimar Therapeutics Aligns Executive Incentives with Milestones - MSN

Jan 28, 2025
pulisher
Jan 27, 2025

Larimar Therapeutics awards key executives performance-based stock - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment - MSN

Jan 27, 2025
pulisher
Jan 26, 2025

JMP Securities maintains $21 target on Larimar Therapeutics stock - MSN

Jan 26, 2025
pulisher
Jan 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Earns “Buy” Rating from HC Wainwright - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia - MSN

Jan 25, 2025
pulisher
Jan 25, 2025

Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Australia

Jan 25, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Sells 6,488 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 25, 2025
pulisher
Jan 25, 2025

Larimar Therapeutics’ SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Nigeria

Jan 25, 2025
pulisher
Jan 24, 2025

Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Larimar Therapeutics, Inc. Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Marketscreener.com

Jan 24, 2025
pulisher
Jan 23, 2025

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - The Manila Times

Jan 23, 2025
pulisher
Jan 23, 2025

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Business Upturn

Jan 23, 2025
pulisher
Jan 23, 2025

Larimar Therapeutics Announces Dosing of Adolescents in - GlobeNewswire

Jan 23, 2025
pulisher
Jan 20, 2025

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN

Jan 20, 2025
pulisher
Jan 19, 2025

Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 19, 2025
pulisher
Jan 08, 2025

JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com

Jan 08, 2025
pulisher
Jan 07, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43 - MarketBeat

Jan 07, 2025
pulisher
Jan 06, 2025

Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock - Yahoo Finance

Jan 06, 2025
pulisher
Jan 05, 2025

Geode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 05, 2025
pulisher
Jan 05, 2025

Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat

Jan 05, 2025

Larimar Therapeutics Inc (LRMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$76.39
price up icon 1.28%
$306.85
price up icon 0.37%
$19.42
price up icon 0.89%
$32.53
price down icon 0.80%
$98.38
price up icon 0.88%
biotechnology ONC
$253.17
price down icon 0.95%
大文字化:     |  ボリューム (24 時間):